CN110346573A - Blood analyzing apparatus - Google Patents
Blood analyzing apparatus Download PDFInfo
- Publication number
- CN110346573A CN110346573A CN201810306831.XA CN201810306831A CN110346573A CN 110346573 A CN110346573 A CN 110346573A CN 201810306831 A CN201810306831 A CN 201810306831A CN 110346573 A CN110346573 A CN 110346573A
- Authority
- CN
- China
- Prior art keywords
- detection device
- protein detection
- protein
- specific albumen
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 45
- 239000008280 blood Substances 0.000 title claims abstract description 45
- 238000002331 protein detection Methods 0.000 claims abstract description 146
- 238000001514 detection method Methods 0.000 claims abstract description 81
- 230000033001 locomotion Effects 0.000 claims abstract description 6
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 17
- 102100032752 C-reactive protein Human genes 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 10
- 101710190759 Serum amyloid A protein Proteins 0.000 claims description 9
- 238000004879 turbidimetry Methods 0.000 claims description 9
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 102000018997 Growth Hormone Human genes 0.000 claims description 4
- 108010051696 Growth Hormone Proteins 0.000 claims description 4
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 3
- 229960004407 chorionic gonadotrophin Drugs 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 230000005611 electricity Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 206010048998 Acute phase reaction Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000011246 composite particle Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 230000001294 luteotrophic effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000006259 progesterone secretion Effects 0.000 description 1
- 230000003946 protein process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
This application discloses a kind of blood analyzing apparatus, it include: protein detection system, the protein detection system can be run parallel with the haemocyte detection system, and the protein detection system includes any specifically Protein Detection device of albumen of detection and the controller connecting with the Protein Detection device；Corresponding multiple operation control parameters of setting needed for the controller is used to detect the specific albumen according to specific albumen, the Protein Detection device of the determining currently assigned detection of Protein Detection device of instruction, and then control the content that the Protein Detection device detects specific albumen described in sample to be tested according to the multiple operation control parameter movement.By the above-mentioned means, the application can be realized while completing haemocyte detection, it is able to detect any specific albumen.
Description
Technical field
This application involves blood analysis technology fields, more particularly to a kind of blood analyzing apparatus.
Background technique
Cellanalyzer is called blood cell analyzer, Hematometer, blood counting instrument etc., is that hospital clinical examines application
One of very extensive instrument, cellanalyzer is generally used for detection various parameters relevant to haemocyte, such as red blood cell
Number, leukocyte differential count, content of hemoglobin etc..
Control however as national related medical policy to antibiotic requirement, medical staff wished in diagnosis early stage
It can judge bacterium infection or virus infection, the specific proteins such as C reactive protein (CRP), which are used as, judges bacterium or disease
The preferred index of poison infection, is proposed and blood cell parameter bundle test in outpatient service.Existing immunity analysis instrument can be independent
The content of specific protein is tested, but if respectively to the haemocyte on cellanalyzer and immunity analysis instrument
Parameter and specific protein parameter measure, and need corresponding two parts of blood samples for acquiring same patient, have aggravated the burden of patient；City
There are also a kind of cellanalyzer that can be detected simultaneously to CRP and blood cell parameter on field, but cellanalyzer
The Protein Detection device of middle setting a kind of this specific protein can only detect CRP, be unable to satisfy in measurement blood cell parameter
While measurement to specific protein parameters other in addition to CRP.
Summary of the invention
The application is not only able to realize and joined to haemocyte mainly solving the technical problems that provide a kind of blood analyzing apparatus
Several detections, and it is able to detect any specific albumen.
In order to solve the above technical problems, the technical solution that the application uses is: providing a kind of blood analyzing apparatus, wrap
Include haemocyte detection system, the equipment further include: protein detection system, the protein detection system can be with the haemocytes
Detection system is run parallel, the protein detection system include any specific albumen of detection Protein Detection device and with the egg
The controller of white detection device connection；The controller is used to determine the currently assigned detection of Protein Detection device according to instruction
Specific albumen, the Protein Detection device detect the corresponding multiple operation control parameters being arranged needed for the specific albumen,
And then it controls the Protein Detection device and is acted according to the multiple operation control parameter to detect tool described in sample to be tested
The content of body protein.
The beneficial effect of the application is: being in contrast to the prior art, the application blood analyzing apparatus is in addition to including blood
Cell detecting system, further includes: protein detection system, the protein detection system can be parallel with the haemocyte detection system
Operation, the protein detection system include the Protein Detection device of any specific albumen of detection and connect with the Protein Detection device
The controller connect；The controller be used to be determined according to instruction the currently assigned detection of Protein Detection device specific albumen,
The Protein Detection device detects the corresponding multiple operation control parameters being arranged needed for the specific albumen, and then described in control
The content of Protein Detection device specific albumen according to the multiple operation control parameter motion detection sample to be tested.By
In the controller that the protein detection system includes independent Protein Detection device and is connect with Protein Detection device, i.e. Protein Detection
System can simultaneously can carry out blood cell parameter and albumen parameter independently of haemocyte detection system, in this way
Detection, the detection for shortening detection time, and carrying out blood cell parameter and albumen parameter simultaneously only need to acquire a pipe blood sample, can
To mitigate the burden of patient's blood sampling；In addition, since the controller can determine the specific egg of currently assigned detection according to instruction
White and Protein Detection device detects the corresponding multiple operation control parameters being arranged needed for specific albumen, then can control
Protein Detection device detects the content of specific albumen in sample to be tested according to multiple operation control parameter movements, by this
Mode can make Protein Detection device be not limited to detect special, fixed specific albumen, but can detecte arbitrary tool
Body protein makes the use scope of blood analyzing apparatus more so as to extend the range that blood analyzing apparatus detects specific albumen
Extensively, more adaptable, it is more in line with the demand of doctor and patient.
Detailed description of the invention
In order to more clearly explain the technical solutions in the embodiments of the present application, make required in being described below to embodiment
Attached drawing is briefly described, it should be apparent that, the drawings in the following description are only some examples of the present application, for
For those of ordinary skill in the art, without creative efforts, it can also be obtained according to these attached drawings other
Attached drawing.Wherein:
Fig. 1 is the structural schematic diagram of one embodiment of the application blood analyzing apparatus；
Fig. 2 is the structural schematic diagram of another embodiment of the application blood analyzing apparatus；
Fig. 3 is the structural schematic diagram of the another embodiment of the application blood analyzing apparatus.
Specific embodiment
Below in conjunction with the attached drawing in the embodiment of the present application, technical solutions in the embodiments of the present application carries out clear, complete
Site preparation description, it is clear that described embodiments are only a part of embodiments of the present application, rather than whole embodiments.Based on this
Embodiment in application, those of ordinary skill in the art are obtained every other under the premise of not making creative labor
Embodiment shall fall in the protection scope of this application.
Refering to fig. 1, Fig. 1 is the structural schematic diagram of one embodiment of the application blood analyzing apparatus, the blood analyzing apparatus
100 include haemocyte detection system 1 and protein detection system 2.
Protein detection system 1 can be run parallel with haemocyte detection system 2, can also be with non-parallel operation.Parallel operation,
Refer to that protein detection system 1 can be run simultaneously with haemocyte detection system 2, to detect respective relevant parameter.Non- parallel fortune
Row, refer to protein detection system 1 can with the non-concurrent operation of haemocyte detection system 2, to detect respective relevant parameter.
Protein detection system 2 includes the Protein Detection device 21 of any specific albumen of detection and connects with Protein Detection device 21
The controller 22 connect；Controller 22 is used for according to specific albumen, the egg for instructing the determining currently assigned detection of Protein Detection device 21
White detection device 21 detects the corresponding multiple operation control parameters being arranged needed for specific albumen, and then controls Protein Detection device
21 detect the content of specific albumen in sample to be tested according to multiple operation control parameter movements.
In the present embodiment, the quantity of Protein Detection device 21 can be more than one, the tool of Protein Detection device 21
Body structure needs the testing principle according to albumen to determine, Protein Detection device 21 may include from sample pretreatment to being examined
Survey finishes necessary structure member needed for process.It certainly, can also if the quantity of Protein Detection device 21 is two or more
With according to the actual situation (such as:, detector is all the same for testing principle, pre-process it is all the same, pre-process it is different, etc.
Deng) and actual demand consider the considerations of (such as: blood analyzing apparatus cost, etc.), come determine from sample pretreatment into
Row detection finishes whether necessary structure member needed for process needs certain structure members to share, and certain structure members are not total
With.Therefore, the specific structure of Protein Detection device 21 is herein and without limitation.More than one Protein Detection device 21 is according to egg
White testing principle, specific structure can be all the same, can also part it is identical, part is not identical, or is all different, herein
Without limitation.
Instruction in present embodiment can be (such as is touched by the input unit that is arranged on blood analyzing apparatus 100
Control display screen etc.) it assigns, it is also possible to assign by the host (such as computer etc.) connecting with blood analyzing apparatus 100,
Instruction is from He Erlai, herein and without limitation.
Multiple operation control parameters, or referred to as multiple detection control parameters, refer to multiple pre- places according to specific albumen
Manage bar part and/or multiple testing conditions, and the corresponding control parameter for needing to configure or being arranged Protein Detection device 21.Such as: blood
Liquid additional amount, dilution additional amount, protein reagent additional amount, reaction incubation time, reaction incubation temperature, detector correlation ginseng
Number, action parameter of associated components etc..For each Protein Detection device, some operation control parameters are identical, have
It is not identical to operate control parameter, therefore, it is necessary first to make Protein Detection device 21 that these operation control parameters be set or configured,
It is ready for subsequent detection.
Protein Detection device 21 is able to detect any specific albumen, as long as the detection of any specific albumen can use albumen
The testing principle of detection device 21 is detected.But different albumen are when specifically detecting, preprocessing process, testing conditions
Deng (i.e. corresponding multiple operation control parameters) be not it is duplicate, need previously according to its corresponding multiple operations control ginseng
Number, is configured or configures to Protein Detection device 21.Therefore, controller 22 is connect with Protein Detection device 21, controller 22
After receiving instruction, according to instruction: the first, the specific albumen of currently assigned detection, second, the specific albumen is examined
The Protein Detection device 21 of survey, then controller 22 can be set according to the specific albumen and its corresponding Protein Detection device information
Multiple operation control parameters of corresponding Protein Detection device 21 are set or configured, and then control albumen configured or that setting completed
Detection device 21 detects the content of specific albumen in sample to be tested.
Specifically, such as, blood analyser has pre-saved the corresponding multiple groups detection of the multiple Protein Detection device
Control parameter (in one group of detection control parameter include multiple detection control parameters) includes according in Protein Detection instruction
Specific albumen and corresponding Protein Detection device information, can complete configuration Protein Detection device carrying out for the specific egg
Required multiple detection control parameters when white detection, controller control the Protein Detection device and are controlled according to the multiple detection
Parameter actions carry out detection operation to sample to be tested, to obtain the content of specific albumen.
The application embodiment blood analyzing apparatus is in addition to including haemocyte detection system, further includes: protein detection system,
The protein detection system can be run parallel with the haemocyte detection system, and the protein detection system includes that detection is any
The Protein Detection device of specific albumen and the controller being connect with the Protein Detection device；The controller is used for according to instruction
Determine that the specific albumen of the currently assigned detection of Protein Detection device, the Protein Detection device detect the specific albumen institute
The corresponding multiple operation control parameters that need to be arranged, and then control the Protein Detection device and controlled according to the multiple operation and joined
Number is acted to detect the content of specific albumen described in sample to be tested.Since the protein detection system includes independent albumen inspection
The controller surveying device and connecting with Protein Detection device, i.e. protein detection system can lead to independently of haemocyte detection system
This mode is crossed, blood cell parameter and albumen parameter can be detected simultaneously, shorten detection time, and carry out blood simultaneously
The detection of cell parameters and albumen parameter only needs to acquire a pipe blood sample, can mitigate the burden of patient's blood sampling；In addition, by institute
Stating controller can determine that the specific albumen of currently assigned detection and Protein Detection device detect specific albumen institute according to instruction
Then the corresponding multiple operation control parameters that need to be arranged can control Protein Detection device and examine under multiple operation control parameters
The content of specific albumen in sample to be tested is surveyed, in this way, Protein Detection device can be made to be not limited to detection special
, fixed specific albumen, but can detecte arbitrary specific albumen, it is specific so as to extend blood analyzing apparatus detection
The range of albumen keeps the use scope of blood analyzing apparatus wider, more adaptable, is more in line with the demand of doctor and patient.
In one embodiment, the quantity of Protein Detection device 21 is more than two, and each Protein Detection device 21 can be examined
Survey specified any specific albumen.
Wherein, more than two Protein Detection devices 21 can detect simultaneously；Controller 22 determines each albumen according to instruction
Specific albumen, each Protein Detection device 21 of the currently assigned detection of detection device 21 detect the correspondence being arranged needed for specific albumen
Multiple operation control parameters, and then control each Protein Detection device 21 simultaneously according to respectively multiple operation control parameters movements
To detect the content of specific albumen in respective sample to be tested.
That is, all Protein Detection devices 21 being equipped on protein detection system can detect simultaneously, at this point, controller
Have according to instructing the specific albumen for determining the currently assigned detection of each Protein Detection device 21, each Protein Detection device 21 to detect
The corresponding multiple operation control parameters being arranged needed for body protein, and then each Protein Detection device 21 is controlled simultaneously according to respective
Multiple operation control parameters are acted to detect the content of specific albumen in respective sample to be tested.
Such as: equipped with Protein Detection device a, Protein Detection device b, Protein Detection device c, egg on protein detection system
White detection device d, Protein Detection device e and Protein Detection device f；Controller determines this 6 Protein Detection dresses according to instruction
Setting the albumen detected respectively is specific albumen a, specific albumen b, specific albumen c, specific albumen d, specific albumen e and specific egg
White f；Detecting the corresponding multiple operation control parameters being arranged needed for the Protein Detection device of this 6 albumen is respectively multiple operations
Control parameter a, multiple operation control parameter b, multiple operation control parameter c, multiple operation control parameter d, multiple operations control
Parameter e and multiple operation control parameter f；And Protein Detection device a, Protein Detection device b, Protein Detection device are controlled simultaneously
C, Protein Detection device d, Protein Detection device e and Protein Detection device f according to respectively multiple operation control parameters act with
Detect the content of specific albumen in respective sample to be tested.
Certainly, the Protein Detection device more than any one can also detect simultaneously, for example, on protein detection system equipped with
Protein Detection device a, Protein Detection device b, Protein Detection device c, Protein Detection device d, Protein Detection device e and albumen
Detection device f；It can specify Protein Detection device a and Protein Detection device b while detecting, also can specify Protein Detection device
B and Protein Detection device c are detected simultaneously, also can specify Protein Detection device d, Protein Detection device e and Protein Detection dress
It sets f while detecting；Or Protein Detection device a and Protein Detection device b are detected simultaneously at the first moment, Protein Detection dress
D, Protein Detection device e and Protein Detection device f are set at the second moment (being later than for the first moment) while detection, etc..
Referring to fig. 2, in one embodiment, which further includes a point blood device 3, divides blood device 3 according to specific albumen
Incubation time is different, and different to the execution sequencing of Protein Detection device 21 divides blood to operate.
Under normal conditions, different specific albumen, reaction incubation time be it is different, according to the incubation of specific albumen
Time is different, and different to the execution sequencing of Protein Detection device 21 of specific albumen divides blood to operate, in order to pass through reaction
Incubation time controls time of entire detection process.Further, the reaction incubation time of specific albumen is longer, can be preferential right
The execution of Protein Detection device 21 of the specific albumen divides blood to operate, and can make the time of entire detection process so as far as possible most
It is short, with the test samples as more as possible within the unit time to the maximum extent, improve detection efficiency.
In a specific practical application, the quantity of Protein Detection device 21 is six.Certainly, according to practical application, albumen
The quantity of detection device 21 can be flexibly equipped with.
Wherein, the specific albumen that above-mentioned protein detection system can detecte includes: c reactive protein, serum amyloid protein
A, human chorionic gonadotrophin, growth hormone, lutropin, alpha-fetoprotein and carcinomebryonic antigen.
C reactive protein (C-reactive protein, CRP) is infected in body or when tissue damage in blood plasma
Some protein (acute protein) steeply risen, activating complement play opsonic action with the phagocytosis for reinforcing phagocyte, remove
Invade body pathogenic microorganism and damage, necrosis, apoptosis histocyte；It is considered as that acute phase is anti-that CRP, which is first,
Albumen is answered, under normal circumstances content denier, its blood concentration sharply increases in acute injury and infection；CRP is clinically most
Common acute-phase response index.
Serum amyloid A protein (Serum Amyloid A protein, SAA) is a kind of Acute reaction protein, with
CRP is similar, to assess Acute-phase protein process；SAA is a sensitive parameter, it starts to rise after inflammatory reaction about 8h
Height, and be more than term of reference upper limit time earlier than CRP, however I d median of the CRP in normal person and the term of reference upper limit
Gap, about 10 times.Only have 5 times in SAA.Mild infection, for example, many virus infections, SAA is increased more than CRP
It is common.In infectious diseases, the absolute rise of SAA is higher than CRP, therefore SAA is measured, especially to " normal " with it is small acute
Phase reaction can provide better identification.
Mature women forms embryo because the ovum of fertilization is moved in uterine cavity after implantation, is fetus mistake in growing
Cheng Zhong, placenta syncytiotrophoblast generate a large amount of human chorionic gonadotrophin (Human Chorionic
Gonadotropin, HCG), it can be recycled and be excreted in urine by pregnant woman blood.When gestation 1~2.5 week, in serum and urine
HCG level can increase rapidly, the 8th week pregnancy period peaked, until beginning within the pregnancy period 4th month is down to medium level, and tieed up always
It holds to third trimester of pregnancy.
Growth hormone (Growth Hormone, GH) has human growth hormone equivalent effect.Can promote bone, internal organ and
Whole body growth promotes protein synthesis, influences fat and mineral metabolism, plays key effect in growth in humans's development.
Lutropin is also known as luteotropin (Luteotropic Hormone, LH), can be because of estrogen secretion before preovulatory not
Foot causes the bad and too early atrophy of corpus luteum development.Corpus luteum development is not full-time, then secreting function is not good enough, keeps progesterone secretion amount insufficient.Face
Bed shows the regular menstrual cycle, but cycle time, or there is a small amount of bleeding in the premenstrual a few days, and blood volume can be unchanged.Before menstruation
The visible glandular secretion of phase endometrial biopsy is bad or uneven.Interstitial edema is unobvious.Basal body temperature biphasic type, but rise slow
Slowly, luteal phase is relatively normal short, generally at 10 days or so.Due to pregnancy period deficiency, infertile or early abortion is often formed.
Alpha-fetoprotein (Alpha Fetoprotein, AFP) is a kind of glycoprotein, belongs to albumin family, mainly by fetus
Liver cell and yolk bag synthesis.Alpha-fetoprotein concentration with higher in fetal circulation, then declines after birth, until after raw
2~March, alpha-fetoprotein was substituted by albumin substantially, more difficult detection in blood, therefore content is extremely low in adult serum.Alpha-fetoprotein
With many important physiological functions, including transportation function, the two-way regulating function as growth regulator, immunosupress, T
Lymphocyte is apoptosis-induced etc..Alpha-fetoprotein and the occurrence and development of liver cancer and kinds of tumors are closely related, in kinds of tumors
It can express higher concentration, can be used as the positive detection index of kinds of tumors.At present clinically mainly as primary carcinoma of liver
Blood serum designated object, diagnosis and curative effect monitoring for primary carcinoma of liver.
Carcinomebryonic antigen (Carcinoembryonic Antigen, CEA) is extracted from colon cancer and embryonic tissue first
A kind of tumor associated antigen is a kind of acidoglycoprotein with human embryos antigenic characteristic, is present in endoderm cell's differentiation
And the cancer cell surface come, it is the structural proteins of cell membrane.It is formed in cytoplasm, is secreted into extracellularly by cell membrane,
Subsequently into ambient body fluid.Therefore, can from a variety of body fluid such as serum, cerebrospinal fluid, milk, gastric juice, Pleural effusions and urine, excrement and
It is detected in excreta.Carcinomebryonic antigen is a kind of broad-spectrum tumor marker, although cannot function as diagnosing the special of certain malignant tumour
Property index, but the antidiastole in malignant tumour, state of illness monitoring, in terms of, still have important clinical value.
In certain practical application, the specific albumen that the protein detection system can detecte is not limited to egg mentioned above
White race class can also be other albumen.
In one embodiment, protein detection system 2 detects specific albumen in sample to be tested by immunoturbidimetry
Content.
Immunoturbidimetry (Turbidimetric inhibition immuno assay) is that antigen-antibody combines dynamic to survey
Determine method.The basic principle is that: when antigen and antibody react and suitable (the general provision antibody of ratio in special dilution system
It is excessive) when, under the action of the poly- agent of rush of the soluble immune complex of formation in dilution system (polyethylene glycol etc.), from liquid phase
It is precipitated, forms particle, reaction solution is made turbidity occur.When antibody concentration is fixed, the amount of the immune complex of formation is with sample
The increase of middle amount of antigen and increase, the turbidity of reaction solution is consequently increased.By the turbidity and series of standards that measure reaction solution
Product control, can calculate the content of antigen in sample.Immunoturbidimetry includes Immunity transmission turbidity, Immune scatter turbidimetry
And immune latex turbidimetry method.
Wherein, in a concrete application, protein detection system is detected in sample to be tested by Immune scatter turbidimetry to be had
The content of body protein.
The basic principle of Immune scatter turbidimetry is: the light of certain wavelength is irradiated along trunnion axis, is encountered when passing through solution anti-
Original antibody complex particle, light are reflected by particle granules, are deflected, and the wavelength of the angle of light deflection and transmitting light and are resisted
Original antibody composite particles size and how many closely related.The intensity for scattering light is directly proportional to the content of compound, i.e., to be measured anti-
Former more, the compound of formation is also more, and scattering light is also stronger.The intensity of light is scattered also with various physical factors, is such as added anti-
Former or antibody time, the power of light source and wavelength, measurement angle etc. are closely related.Immune scatter turbidimetry is divided into rate again and dissipates
Penetrate turbidimetry and terminal scattered light urbidmetry.
It is not limited to detection method mentioned above, Protein Detection device can also pass through scattering turbidimetry performance rate method, scattering ratio
The detection methods such as turbid end-point method detect albumen.Referring to Fig. 3, in one embodiment, Protein Detection device 21 includes swashing
Optical detection circuit 211, reagent adding apparatus 212, temperature control circuit 213 and detection cell 214, laser sensor circuit 211, reagent add
Enter device 212 and temperature control circuit 213 is connect with controller 22 respectively；Under control of controller 22, laser sensor circuit 211
Emit the sample to be tested in laser irradiation detection cell 214, and is examined by detecting the scattering light after sample to be tested scatters
Survey the content of specific albumen in sample to be tested；Under control of controller 22, default reagent is added reagent adding apparatus 212
In detection cell 214；Under control of controller 22, temperature control circuit 213 control detection cell 214 in protein reagent, dilution and
The incubation temperature of blood sample reaction.The principle that the Protein Detection device 21 of present embodiment detects albumen is Immune scatter turbidimetry.
Wherein, haemocyte detection system is for analyzing parameter relevant to haemocyte in blood sample.Such as: in analysis blood sample
Red blood cell, blood platelet, leucocyte and the relevant parameter of hemoglobin.
The foregoing is merely presently filed embodiments, are not intended to limit the scope of the patents of the application, all to utilize this
Equivalent structure or equivalent flow shift made by application specification and accompanying drawing content, it is relevant to be applied directly or indirectly in other
Technical field similarly includes in the scope of patent protection of the application.
Claims (10)
1. a kind of blood analyzing apparatus, including haemocyte detection system, which is characterized in that the equipment further include:
Protein detection system, the protein detection system include any specific albumen of detection Protein Detection device and with the egg
The controller of white detection device connection；The controller is used to determine the currently assigned detection of Protein Detection device according to instruction
Specific albumen, the Protein Detection device detect the corresponding multiple operation control parameters being arranged needed for the specific albumen,
And then it controls the Protein Detection device and is acted according to the multiple operation control parameter to detect tool described in sample to be tested
The content of body protein.
2. equipment according to claim 1, which is characterized in that the quantity of the Protein Detection device is two or more, often
A Protein Detection device can detect specified any specific albumen.
3. equipment according to claim 2, which is characterized in that more than two Protein Detection devices can be examined simultaneously
It surveys；The controller determines the specific albumen, each described of each currently assigned detection of Protein Detection device according to instruction
Protein Detection device detects the corresponding multiple operation control parameters being arranged needed for the specific albumen, and then controls simultaneously each
The Protein Detection device has according to the respective sample to be tested of respective the multiple operation control parameter motion detection
The content of body protein.
4. equipment according to claim 2, which is characterized in that the equipment further includes a point blood device, described to divide blood device
Different according to the incubation time of the specific albumen, different to Protein Detection device execution sequencing divides blood to operate.
5. equipment according to claim 1-4, which is characterized in that the quantity of the Protein Detection device is six
It is a.
6. equipment according to claim 1, which is characterized in that the specific albumen packet that the protein detection system can detecte
It includes: c reactive protein, serum amyloid A protein, human chorionic gonadotrophin, growth hormone, lutropin, alpha-fetoprotein
And carcinomebryonic antigen.
7. equipment according to claim 1, which is characterized in that the protein detection system detects institute by immunoturbidimetry
State the content of specific albumen described in sample to be tested.
8. equipment according to claim 7, which is characterized in that the protein detection system is examined by Immune scatter turbidimetry
Survey the content of specific albumen described in the sample to be tested.
9. equipment according to claim 1, which is characterized in that the Protein Detection device includes laser sensor circuit, examination
Agent adding apparatus, temperature control circuit and detection cell, the laser sensor circuit, the reagent adding apparatus and temperature control electricity
Road is connect with the controller respectively；Under the control of the controller, the laser sensor circuit transmitting laser irradiation detection
Sample to be tested in pond, and the sample to be tested is detected by detecting the scattering light after sample to be tested scattering
Described in specific albumen content；Under the control of the controller, default reagent is added and detects by the reagent adding apparatus
In pond；Under the control of the controller, the temperature control circuit controls protein reagent, dilution and blood sample in the detection cell
The incubation temperature of reaction.
10. equipment according to claim 1, which is characterized in that the haemocyte detection system for analyze in blood sample with
The relevant parameter of haemocyte.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810306831.XA CN110346573A (en) | 2018-04-08 | 2018-04-08 | Blood analyzing apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810306831.XA CN110346573A (en) | 2018-04-08 | 2018-04-08 | Blood analyzing apparatus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110346573A true CN110346573A (en) | 2019-10-18 |
Family
ID=68173209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810306831.XA Withdrawn CN110346573A (en) | 2018-04-08 | 2018-04-08 | Blood analyzing apparatus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110346573A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114062036A (en) * | 2020-07-31 | 2022-02-18 | 深圳市帝迈生物技术有限公司 | Blood sample distribution method, blood detection device, and computer-readable storage medium |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090075305A1 (en) * | 2005-05-02 | 2009-03-19 | The Brigham And Womern's Hospital, Inc. | Diagnostic serum antibody profiling |
| CN103336130A (en) * | 2013-06-21 | 2013-10-02 | 嘉善加斯戴克医疗器械有限公司 | Whole-blood immunoassay device and blood analyzer with same |
| CN104515857A (en) * | 2013-09-30 | 2015-04-15 | 深圳迈瑞生物医疗电子股份有限公司 | Whole blood C-reactive protein measurement method, whole blood C-reactive protein measurement apparatus and sample analysis meter |
| CN105378478A (en) * | 2014-07-01 | 2016-03-02 | 深圳迈瑞生物医疗电子股份有限公司 | Whole blood sample testing method and blood tester |
| CN105699380A (en) * | 2016-03-23 | 2016-06-22 | 深圳市帝迈生物技术有限公司 | Analysis equipment and method for simultaneously measuring CRP (C-Reactive Protein) and blood routine |
| CN205656141U (en) * | 2016-03-23 | 2016-10-19 | 深圳市帝迈生物技术有限公司 | But conventional analytical equipment of simultaneous measurement CRP and blood |
| CN106124751A (en) * | 2016-08-17 | 2016-11-16 | 江苏英诺华医疗技术有限公司 | Blood cell and analysis of biochemical instrument and method |
| CN208076544U (en) * | 2018-04-08 | 2018-11-09 | 深圳市帝迈生物技术有限公司 | Blood analyzing apparatus |
| CN110346574A (en) * | 2018-04-08 | 2019-10-18 | 深圳市帝迈生物技术有限公司 | Method, blood analyzing apparatus and the device of Protein Detection device multiplexing detection albumen |
-
2018
- 2018-04-08 CN CN201810306831.XA patent/CN110346573A/en not_active Withdrawn
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090075305A1 (en) * | 2005-05-02 | 2009-03-19 | The Brigham And Womern's Hospital, Inc. | Diagnostic serum antibody profiling |
| CN103336130A (en) * | 2013-06-21 | 2013-10-02 | 嘉善加斯戴克医疗器械有限公司 | Whole-blood immunoassay device and blood analyzer with same |
| CN104515857A (en) * | 2013-09-30 | 2015-04-15 | 深圳迈瑞生物医疗电子股份有限公司 | Whole blood C-reactive protein measurement method, whole blood C-reactive protein measurement apparatus and sample analysis meter |
| CN105378478A (en) * | 2014-07-01 | 2016-03-02 | 深圳迈瑞生物医疗电子股份有限公司 | Whole blood sample testing method and blood tester |
| CN105699380A (en) * | 2016-03-23 | 2016-06-22 | 深圳市帝迈生物技术有限公司 | Analysis equipment and method for simultaneously measuring CRP (C-Reactive Protein) and blood routine |
| CN205656141U (en) * | 2016-03-23 | 2016-10-19 | 深圳市帝迈生物技术有限公司 | But conventional analytical equipment of simultaneous measurement CRP and blood |
| CN106124751A (en) * | 2016-08-17 | 2016-11-16 | 江苏英诺华医疗技术有限公司 | Blood cell and analysis of biochemical instrument and method |
| CN208076544U (en) * | 2018-04-08 | 2018-11-09 | 深圳市帝迈生物技术有限公司 | Blood analyzing apparatus |
| CN110346574A (en) * | 2018-04-08 | 2019-10-18 | 深圳市帝迈生物技术有限公司 | Method, blood analyzing apparatus and the device of Protein Detection device multiplexing detection albumen |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114062036A (en) * | 2020-07-31 | 2022-02-18 | 深圳市帝迈生物技术有限公司 | Blood sample distribution method, blood detection device, and computer-readable storage medium |
| CN114062036B (en) * | 2020-07-31 | 2023-12-29 | 深圳市帝迈生物技术有限公司 | Blood sample distribution method, blood detection device, and computer-readable storage medium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110346574A (en) | Method, blood analyzing apparatus and the device of Protein Detection device multiplexing detection albumen | |
| US20120015350A1 (en) | Lateral flow strip and uses thereof | |
| CN101509917A (en) | Methods and kits for predicting risk for preterm labor | |
| JPS6119268B2 (en) | ||
| JP2002510045A (en) | Flow-based cell count calculator for analyzing common diagnostic factors in cells and body fluids | |
| PT2049906E (en) | Assay and kit for predicting implantation success in assisted fertilisation | |
| WO2018157831A1 (en) | Lung cancer monitoring kit and application method thereof | |
| CN104395755A (en) | Methods and compositions for personalized medicine by point-of-care devices for FSH, LH, HCG and BNP | |
| Ren et al. | High serum levels of follistatin in patients with ovarian cancer | |
| Van der Gaast et al. | Impact of ovarian stimulation on mid-luteal endometrial tissue and secretion markers of receptivity | |
| CN103163305B (en) | Method for quickly judging woman pregnancy conditions | |
| CN110346573A (en) | Blood analyzing apparatus | |
| CN102053157A (en) | Test strip for fast detecting premature rupture of fetal membranes | |
| Bragança et al. | Using pregnancy-associated glycoproteins to provide early pregnancy diagnosis in Nelore cows | |
| CN208076544U (en) | Blood analyzing apparatus | |
| Sia et al. | Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations | |
| RU2425641C1 (en) | Method of predicting risk of development of abnormal uterine bleedings in puberty period in teenage girls | |
| Mor et al. | Same-day confirmation of intrauterine pregnancy failure in women with first-and early second-trimester bleeding | |
| CN109085355A (en) | Application of serum protein marker combination in screening, diagnosis and treatment of lung cancer | |
| CN103134935A (en) | Making method of immunochromatographic test paper for detecting premature rupture of fetal membranes | |
| CN101858917B (en) | Kit for detecting premature rupture of membrane by taking Axl as detection index and preparation method thereof | |
| CN101358964B (en) | Cancer diagnosing kit containing HLA-G monoclonal antibodies and use thereof | |
| Chen et al. | Clinical application of immunomagnetic reduction for quantitative measurement of insulin-like growth factor binding protein-1 in the prediction of pregnant women with preterm premature rupture of membranes | |
| CN103267851A (en) | A kit for detecting premature rupture of membranes and its preparation method | |
| Shao et al. | Quantitative analysis of hormones and inflammatory cytokines in Chlamydia trachomatis-infected women with tubal ectopic pregnancy and early intrauterine pregnancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191018 |
|
| WW01 | Invention patent application withdrawn after publication |